Dubin-Johnson syndrome is a rare genetic disorder characterized by impaired liver function. It is estimated to affect approximately 1 in every 40,000 to 90,000 individuals worldwide. This condition is more prevalent in certain populations, such as Ashkenazi Jews and individuals from the Middle East. The syndrome is caused by mutations in a specific gene involved in the transport of bilirubin, a pigment produced by the liver. Although Dubin-Johnson syndrome is relatively uncommon, it is important to diagnose and manage the condition to prevent complications and ensure optimal liver health.
Dubin-Johnson syndrome is a rare genetic disorder that affects the liver's ability to process and excrete bilirubin, a yellow pigment produced during the breakdown of red blood cells. This condition is inherited in an autosomal recessive manner, meaning that both parents must carry a copy of the mutated gene for their child to be affected.
The prevalence of Dubin-Johnson syndrome is estimated to be quite low, with only a few hundred cases reported worldwide. It is more commonly observed in certain populations, such as individuals of Middle Eastern, North African, and Mediterranean descent. However, due to the rarity of this condition and the lack of comprehensive population studies, the exact prevalence remains uncertain.
Although Dubin-Johnson syndrome is generally considered a benign condition, it can lead to chronic jaundice (yellowing of the skin and eyes) and intermittent episodes of dark urine. These symptoms may fluctuate in severity throughout a person's life. While the disorder itself does not typically cause significant health problems, it is important for individuals with Dubin-Johnson syndrome to be aware of potential drug interactions that could further impair liver function.